Latest News and Press Releases

Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program

Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics Announces Expansion into Parkinson’s Disease Clinical Research with Lead Compound ALX-001 Following IND Acceptance

Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development

Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.